Generic Immunosuppressants in Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 3, 2011, Pages 285-290

  Cutler, Corey ^a   Kesselheim, Aaron ^b   Gabardi, Steven ^b   Andersson, Borje S ^c   Carpenter, Paul ^d   Khoury, Hanna J ^e   Litzow, Mark ^f   Rowley, Scott D ^g   Lanum, Scott ^d   Leather, Helen ^h   Tina Shih, Ya Chen ⁱ   Gale, Robert Peter ^j   Wingard, John R ^k   Appelbaum, Frederick R ^d   Anasetti, Claudio ^l  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d USA   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^h NucleusX   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j CELGENE CORPORATION   (United States)

^k UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^l H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

DRUG APPROVAL; DRUG COST; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG MONITORING; FOOD AND DRUG ADMINISTRATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NOTE; PATIENT EDUCATION; PRACTICE GUIDELINE;

DRUG COSTS; DRUG MONITORING; DRUGS, GENERIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; PATIENT EDUCATION AS TOPIC; TACROLIMUS; THERAPEUTIC EQUIVALENCY;

EID: 79551688415     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.11.006     Document Type: Note

References (27)

1. Food and Drug Administration. Abbreviated New Drug Application (ANDA): generics. Available at: Accessed September 15, 2010. http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/default.htm.
2. Tichy E, Alloway RR. Generic immunosuppressants. Available at: Accessed January 12, 2010. http://www.a-s-t.org/rss/all.xml.
3. Food and Drug Administration. Orange Book preface. Available at: Accessed September 15, 2010. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm.
4. Davit B.M., Nwakama P.E., Buehler G.J., et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009, 43:1583-1597.
5. Kesselheim A.S., Misono A.S., Lee J.L., et al. Clinical equivalence of generic and brand name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008, 300:2514-2526.
6. Kesselheim A.S., Stedman M.R., Bubrick E.J., et al. Seizure outcomes following the use of generic versus brand name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010, 70:605-621.
7. Makus K.G., McCormick J. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Ther 2007, 29:334-341.
8. Reiffel J.A., Kowey P.R. Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias. Am J Cardiol 2000, 85:1151-1153.
9. Christians U., Klawitter J., Clavijo C.F. Bioequivalence testing of immunosuppressants: concepts and misconceptions. Kidney Int 2010, 115(Suppl):S1-S7.
10. Food and Drug Administration. Draft guidance on sirolimus. Available at: Accessed November 4, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM089640.pdf.
11. Food and Drug Administration. Guidance on tacrolimus. Available at: Accessed. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM181006.pdf.
12. Abdulnour H.A., Araya C.E., Dharnidharka V.R. Comparison of generic tacrolimus and Prograf drug levels in a pediatric kidney transplant program. Pediatr Transplant 2010, 14(8):1007-1011.
13. McDevitt-Potter L, Sadaka B, Tichy E, et al. Experience with generic tacrolimus conversion. Submitted 2010.
14. Corzo H, et al. A post-hoc analysis of the safety and efficacy of tacrolimus (Prograf) versus a generic formulation of tacrolimus (Tenacrine) as primary immunosuppressive therapy in LRD and CAD adults and pediatric renal transplant recipients. Presented at the 22nd International Congress of the Transplantation Society, 2008. August 10-14, 2008, Sydney, Australia.
15. Petan J.A., Undre N., First M.R., et al. Physiochemical properties of generic formulations of tacrolimus in Mexico. Transplant Proc 2008, 40:1439-1442.
16. Crespo M., Mir M., Marin M., et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc 2009, 41:2115-2117.
17. Guleria S., Kamboj M., Chatterjee A., et al. Generic tacrolimus (Pan Graf) in renal transplantation: an experience of 155 recipients in India. Transplant Proc 2008, 40:2237-2239.
18. Kim S.J., Huh K.H., Han D.J., et al. A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation. Transplant Proc 2009, 41:1671-1674.
19. Videla C., Godoy C. Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillance and outcome. Transplant Proc 2007, 39:602-605.
20. Alloway R.R., Isaacs R., Lake K., et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant 2003, 3:1211-1215.
21. Uber P.A., Ross H.J., Zuckermann A.O., et al. Generic drug immunosuppression in thoracic transplantation: an ISHLT educational advisory. J Heart Lung Transplant 2009, 28:655-660.
22. Sabatini S., Ferguson R.M., Helderman J.H., et al. Drug substitution in transplantation: a National Kidney Foundation white paper. Am J Kidney Dis 1999, 33:389-397.
23. Kovarik J.M., Noe A., Wang Y., et al. Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus. Eur J Clin Pharmacol 2006, 62:361-366.
24. Shrank W.H., Hoang T., Ettner S.L., et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 2006, 166:332-337.
25. Kane S.V., Accortt N.A., Magowan S., et al. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther 2009, 29:855-862.
26. Shah N.R., Hirsch A.G., Zacker C., et al. Predictors of first-fill adherence for patients with hypertension. Am J Hypertens 2009, 22:392-396.
27. Shah N.R., Hirsch A.G., Zacker C., et al. Factors associated with first-fill adherence rates for diabetic medications: a cohort study. J Gen Intern Med 2009, 24:233-237.